Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$22.72 – $42.81
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $715.0K | $2.6M | $4.0M | $13.8M | $18.0M | $33.6M | $75.6M | $121.4M |
| Cost of revenue | $3.4M | $2.6M | $2.4M | $3.7M | $7.2M | $5.1M | $13.5M | $16.5M |
| Gross profit | −$2.7M | −$79.0K | $1.7M | $10.1M | $10.8M | $28.5M | $62.0M | $104.8M |
| Gross margin | -377.8% | -3.1% | 41.4% | 72.9% | 59.9% | 84.8% | 82.1% | 86.4% |
| R&D | $6.9M | $6.5M | $4.0M | $5.0M | $5.2M | $5.6M | $7.0M | $8.9M |
| Operating income | −$13.7M | −$11.4M | −$11.7M | −$8.8M | −$13.4M | −$13.2M | −$5.0M | $7.3M |
| EBITDA | −$11.7M | −$8.5M | −$8.6M | −$5.3M | −$7.5M | −$7.5M | −$561.0K | $10.1M |
| Net income | −$11.7M | −$11.3M | −$11.5M | −$7.5M | −$14.6M | −$13.7M | −$3.7M | $2.1M |
| Net margin | -1635.4% | -439.4% | -285.2% | -54.6% | -81.1% | -40.9% | -4.9% | 1.7% |
| EPS (diluted) | -1.14 | -0.66 | -0.47 | -0.23 | -0.43 | -0.38 | -0.10 | 0.05 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $160M | $0.22 | $0.21–$0.24 | 1 |
| 2027 | $202M | $0.58 | $0.54–$0.63 | 1 |
| 2028 | $250M | $0.95 | $0.87–$1.02 | 1 |
| 2029 | $302M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
KUROS BIOSCIENCE ORD NEW
No one on the platform currently holds CSBTF.
No tracked institution reports a position in CSBTF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2016-08-22 | 1-for-100reverse |
No one on the platform has traded CSBTF yet.
| +0.00% |
| $2.0B |
| — |
| NPPNYNippon Shinyaku Co., Ltd. | $6.00 | +0.00% | $1.6B | — |
| NURPFNeuren Pharmaceuticals Limited | $9.27 | +0.00% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 14.5× sales vs its 6.0× historical median P/S.
Fair value ≈ $9.45 · price $22.72 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.